Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) Non Operating Income (2021 - 2025)

SAB Biotherapeutics' Non Operating Income history spans 5 years, with the latest figure at -$1.1 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 21.31% year-over-year to -$1.1 million; the TTM value through Dec 2025 reached $62.2 million, up 606.71%, while the annual FY2025 figure was $62.2 million, 606.71% up from the prior year.
  • Non Operating Income reached -$1.1 million in Q4 2025 per SABSW's latest filing, down from $58.1 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $58.1 million in Q3 2025 to a low of -$4.0 million in Q4 2023.
  • Average Non Operating Income over 5 years is $3.9 million, with a median of $134397.0 recorded in 2023.
  • Peak YoY movement for Non Operating Income: crashed 36168.02% in 2023, then soared 13108.14% in 2024.
  • A 5-year view of Non Operating Income shows it stood at -$450448.0 in 2021, then surged by 102.45% to $11043.0 in 2022, then plummeted by 36168.02% to -$4.0 million in 2023, then soared by 65.21% to -$1.4 million in 2024, then grew by 21.31% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Non Operating Income are -$1.1 million (Q4 2025), $58.1 million (Q3 2025), and -$382209.0 (Q2 2025).